Preeclampsia Drugs Market Report 2026

Preeclampsia Drugs Market Overview

• Preeclampsia Drugs market size has reached to $1.37 billion in 2025 • Expected to grow to $2.37 billion in 2030 at a compound annual growth rate (CAGR) of 11.8% • Growth Driver: Rising Diabetes Cases In Pregnancy Fueling Growth In The Preeclampsia Drug Market • Market Trend: Leading Companies In The Preeclampsia Medicine Market Pursuing Innovative Drug Solutions • North America was the largest region in 2025.

What Is Covered Under Preeclampsia Drugs Market?

Preeclampsia drugs refer to medications that manage and treat the condition of pre-eclampsia, a serious pregnancy complication characterized by high blood pressure and damage to organs such as the liver and kidneys. These drugs are typically prescribed by healthcare professionals to pregnant women diagnosed with preeclampsia to help lower blood pressure and prevent further complications. The main types of preeclampsia drugs are mild preeclampsia and severe preeclampsia. Mild preeclampsia is a medical disorder that occurs in some pregnant women, usually after the 20th week of pregnancy. They are available for various treatments, such as medication to lower blood pressure (B.P.), corticosteroids and anticonvulsant medication and are administered through various routes, such as the oral route, the parenteral route and others. They are available in various distribution channels, such as hospital pharmacies, retail pharmacies, online pharmacies and others and utilized by various end-users, such as hospitals, specialty clinics, diagnostic centers and others.

What Is The Preeclampsia Drugs Market Growth Forecast?

The preeclampsia drugs market size is expected to see rapid growth in the next few years. It will grow to $2.37 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to advancements in drug formulations, expansion of healthcare infrastructure, rising demand for outpatient maternal care, integration of digital health solutions, increased R&D in precision medicine for pregnancy complications. Major trends in the forecast period include rising incidence of preeclampsia among pregnant women, development of novel antihypertensive drugs, increased focus on maternal and fetal health monitoring, growth of hospital pharmacy and specialty clinics distribution, adoption of combination therapies for severe cases.

Global Preeclampsia Drugs Market Segmentation

1) By Type: Mild Preeclampsia, Severe Preeclampsia 2) By Treatment: Medication to Lower Hypertension (B.P), Corticosteroids, Anticonvulsants Medication 3) By Route of Administration: Oral, Parenteral, Other Route of Administration 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels 5) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users Subsegments: 1) By Mild Preeclampsia: Blood Pressure Management 2) By Severe Preeclampsia: Antihypertensive Medications, Magnesium Sulfate Therapy

What Is The Driver Of The Preeclampsia Drugs Market?

The rise in diabetes cases among pregnant women is expected to propel the growth of the preeclampsia drug market going forward. Diabetes is a metabolic disease that is chronic and characterized by high blood glucose (or blood sugar) levels. Preeclampsia is a harmful pregnancy condition with elevated blood pressure and organ damage. Metformin, a preeclampsia medicine, is widely used in pregnant women with preterm preeclampsia. For instance, in June 2024, according to the National Health Service, a UK-based government department, in 2023, the NHS identified over half a million (549,000) additional individuals in England at risk of developing type 2 diabetes, bringing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This represents a significant increase compared to 3,065,825 in 2022, highlighting a rise of nearly 20%. Therefore, the rise in diabetes cases among pregnant women will drive the preeclampsia drug industry.

Key Players In The Global Preeclampsia Drugs Market

Major companies operating in the preeclampsia drugs market are AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Boehringer Ingelheim Group, Viatris Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Otsuka Pharmaceutical Co. Ltd., Mallinckrodt Pharmaceuticals Limited, Union Chimique Belge SA, Kyowa Kirin Co Ltd, Comanche Biopharma Corp

Global Preeclampsia Drugs Market Trends and Insights

Major companies in the preeclampsia medicine market are focusing on developing advanced therapies, such as small interfering RNA (siRNA) treatments, to address serious unmet medical needs with novel mechanisms of action. siRNA investigational therapies refer to a class of medicines designed to silence or turn off specific genes responsible for causing a disease, offering a targeted approach to treatment. For instance, in March 2023, Comanche Biopharma Corp., a US-based biopharmaceutical firm, revealed that the Food and Drug Administration (FDA) has approved an investigational new drug (IND) application for CBP-4888 Comanche's unique siRNA treatment to treat preeclampsia. CBP-4888 is a siRNA therapy given subcutaneously and reduces the synthesis of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta. The placenta's overproduction of the protein sFLT1, which enters the mother's circulation, is the primary cause of preeclampsia. CBP-4888 can alleviate the symptoms of preeclampsia, such as high blood pressure and organ damage and may allow for the safe extension of pregnancy.

What Are Latest Mergers And Acquisitions In The Preeclampsia Drugs Market?

In March 2024, ASKA Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, partnered with Red Arrow Therapeutics, Inc., to jointly research a novel treatment for preeclampsia. This partnership aims to leverage ASKA’s expertise in maternal health and Red Arrow’s pH-sensitive nanomedicine technology to develop a targeted, safer, and more effective therapy for preeclampsia. Red Arrow Therapeutics Inc. is a US-based biotechnology company focused on developing new cancer treatments.

Regional Insights

North America was the largest region in the preeclampsia drugs market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Preeclampsia Drugs Market?

The preeclampsia drugs market consists of sales of labetalol, methyldopa and magnesium sulfate (prevent seizures). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Preeclampsia Drugs Market Report 2026?

The preeclampsia drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the preeclampsia drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.